Overview
Iressa Follow-up Trial
Status:
Completed
Completed
Trial end date:
2015-05-01
2015-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AstraZenecaTreatments:
GefitinibCriteria
Inclusion Criteria:- Provision of written informed consent to participate in the trial.
- Female or male aged 18 years and over.
- Patients with previously diagnosed cancer who have been treated with ZD1839 in a
parent ZD1839 clinical trial and may benefit from continuation
Exclusion Criteria:
- Known severe hypersensitivity to ZD1839
- Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's
Wort.
- Withdrawal from a parent ZD1839 trial because of tumor progress